Anthony Molloy - 07 Dec 2021 Form 3 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Lgl & Compliance Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 07 Dec 2021
Net transactions value: $0
Form type: 3
Filing time: 17 Dec 2021, 18:58:06 UTC
Next filing: 10 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PCRX	Common Stock						15,550	07 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	15,000	$60.96	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	10,000	$68.89	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	22,000	$47.65	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	26,300	$43.54	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	8,750	$38.35	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	3,125	$34.38	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	10,000	$44.20	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	3,000	$40.34	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	4,000	$67.00	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	5,500	$79.43	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	5,000	$81.00	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							07 Dec 2021	Common Stock	12,500	$56.32	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 15,550 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 6,000 restricted stock units that vest in four equal annual installments on June 3, 2022, June 3, 2023, June 3, 2024 and June 3, 2025, (ii) 6,600 restricted stock units that vest in three equal annual installments on June 3, 2022, June 3, 2023 and June 3, 2024, (iii) 2,200 restricted stock units that vest in two equal annual installments on June 3, 2022 and June 3, 2023 and (iv) 750 restricted stock units that vest on June 3, 2022, in each case, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
F3	The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
F4	The option vested and became exercisable as to 25% of the option shares on December 9, 2014 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.